Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
21
Recruiting, any sponsor type, condition "Duchenne"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed131
21 trials
Showing 1 to 21, recently updated first.
- A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)Pivotal-lookingRecruiting
Solid Biosciences Inc.Industry
NCT07160634 · 80 participants (planned) · Start Oct 22, 2025 · Primary completion Jan 2029
Drug: SGT-003; Placebo · For: Duchenne Muscular Dystrophy
Sites: Little Rock, Arkansas; Flower Mound, Texas; Norfolk, Virginia · 13 sites in all
Satellos Bioscience, Inc.Industry
NCT06867107 · 30 participants (planned) · Start Sep 25, 2025 · Primary completion Sep 30, 2027
Drug: SAT-3247 · For: Duchenne Muscular Dystrophy (DMD)
Sites: Los Angeles, California; St Louis, Missouri; Columbus, Ohio · 6 sites in all
Keros Therapeutics, Inc.Industry
NCT07704099 · 36 participants (planned) · Start Sep 25, 2026 · Primary completion Aug 26, 2028
Drug: KER-065 · For: Duchenne Muscular Dystrophy
Sites: Tbilisi, Georgia; Auckland, New Zealand; Christchurch, New Zealand · 4 sites in all
Vanderbilt University Medical CenterAcademic, hospital or other
NCT07642635 · 30 participants (planned) · Start Dec 2026 · Primary completion Sep 2030
Drug: Semaglutide (Rybelsus®) · For: Duchenne Muscular Dystrophy (DMD)
Sites: Nashville, Tennessee
Sarepta Therapeutics, Inc.Industry
NCT07542314 · 20 participants (planned) · Start Nov 30, 2026 · Primary completion Aug 31, 2027
Drug: ELEVIDYS; Sirolimus and 2 more · For: Duchenne Muscular Dystrophy
Sites: Nashville, Tennessee; Houston, Texas
- A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 SkippingPivotal-lookingRecruiting
Avidity Biosciences, Inc.Industry
NCT07587242 · 70 participants (planned) · Start Sep 1, 2026 · Primary completion May 2029
Drug: AOC 1044; Placebo · For: Muscular Dystrophies; Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy); Muscular Disorders, Atrophic and 11 more
Sites: Westmead, Australia; Leuven, Belgium; Liège, Belgium · 20 sites in all
Precision BioSciences, Inc.Industry
NCT07429240 · 18 participants (planned) · Start Apr 24, 2026 · Primary completion Nov 2029
Drug: PBGENE-DMD (IV) · For: Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD
Sites: Little Rock, Arkansas; St Louis, Missouri
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT06147414 · 550 participants (planned) · Start Oct 23, 2024 · Primary completion May 2027
Drug: Blood sample · For: Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including; Sickle Cell Disease; Cystic Fibrosis and 12 more
Sites: Paris, France
University of FloridaAcademic, hospital or other
NCT07766980 · 20 participants (planned) · Start Jul 27, 2026 · Primary completion Dec 2028
Drug: VM100 Nutritional Supplement · For: Duchenne Muscular Dystrophy; Duchenne Disease; Muscular Dystrophy in Children and 2 more
Sites: Gainesville, Florida
Catalyst Pharmaceuticals, Inc.Industry
NCT06564974 · 250 participants (planned) · Start Sep 25, 2024 · Primary completion Feb 2032
Drug: Vamorolone · For: Duchenne Muscular Dystrophy
Sites: Phoenix, Arizona; Little Rock, Arkansas; Loma Linda, California · 33 sites in all
Vanderbilt University Medical CenterAcademic, hospital or other
NCT07172971 · 10 participants (planned) · Start Jul 1, 2026 · Primary completion Aug 1, 2027
Drug: SGLT-2 inhibitor; SGLT2 inhibitor · For: Duchenne Muscular Dystrophy (DMD)
Sites: Nashville, Tennessee
Anne M. ConnollyAcademic, hospital or other
NCT05412394 · 26 participants (planned) · Start Apr 30, 2021 · Primary completion Aug 2028
Drug: Prednisolone · For: Duchenne Muscular Dystrophy
Sites: Chicago, Illinois; Cincinnati, Ohio; Columbus, Ohio · 4 sites in all
Entrada Therapeutics, Inc.Industry
NCT07037862 · 24 participants (planned) · Start Jun 30, 2025 · Primary completion Mar 28, 2029
Drug: ENTR-601-44; ENTR-601-44 - matching placebo · For: Duchenne Muscular Dystrophy (DMD)
Sites: Ghent, Belgium; Leuven, Belgium; Liège, Belgium · 14 sites in all
Entrada Therapeutics, Inc.Industry
NCT07038824 · 24 participants (planned) · Start Aug 30, 2025 · Primary completion Mar 1, 2029
Drug: ENTR-601-45; ENTR-601-45 - matching placebo · For: Duchenne Muscular Dystrophy (DMD)
Sites: Ghent, Belgium; Leuven, Belgium; Liège, Belgium · 15 sites in all
- Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular DystrophyPivotal-lookingRecruiting
ItalfarmacoIndustry
NCT05933057 · 138 participants (planned) · Start Feb 19, 2024 · Primary completion Feb 2028
Drug: Givinostat; Placebo · For: Duchenne Muscular Dystrophy
Sites: Leuven, Belgium; Vancouver, Canada; London, Canada · 29 sites in all
- Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)Pivotal-lookingRecruiting
Dyne TherapeuticsIndustry
NCT07608432 · 90 participants (planned) · Start Jun 2026 · Primary completion Dec 2030
Drug: Zeleciment Rostudirsen (DYNE-251); Placebo · For: Duchenne Muscular Dystrophy (DMD); Muscular Dystrophy, Duchenne; Muscular Dystrophy (DMD) and 10 more
Sites: Hillsborough, North Carolina
University of FloridaAcademic, hospital or other
NCT06290713 · 50 participants (planned) · Start Jun 5, 2024 · Primary completion Nov 2026
Drug: Tadalafil; Placebo · For: Duchenne Muscular Dystrophy; Duchenne Disease; Muscular Dystrophy and 4 more
Sites: Gainesville, Florida
- Trial of Cell Based Therapy for DMDRecruiting
Masonic Cancer Center, University of MinnesotaAcademic, hospital or other
NCT06692426 · 8 participants (planned) · Start Mar 20, 2025 · Primary completion Mar 3, 2027
Drug: MyoPAXon; Tacrolimus · For: Duchenne Muscular Dystrophy
Sites: Minneapolis, Minnesota
- Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability StudyPivotal-lookingRecruiting
ItalfarmacoIndustry
NCT03373968 · 206 participants (planned) · Start Oct 24, 2017 · Primary completion Dec 2029
Drug: Givinostat · For: Duchenne Muscular Dystrophy
Sites: Sacramento, California; San Diego, California; Hartford, Connecticut · 39 sites in all
ItalfarmacoIndustry
NCT06769633 · 18 participants (planned) · Start Jan 2, 2025 · Primary completion Dec 2029
Drug: Givinostat Hydrochloride; Givinostat Hydrochloride - Cohort 2 · For: Duchenne Muscular Dystrophy
Sites: Brussels, Belgium; Milan, Italy; Roma, Italy · 9 sites in all
Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
NCT06900049 · 12 participants (planned) · Start Oct 24, 2024 · Primary completion Sep 20, 2026
Drug: LE051 · For: Duchenne Muscular Dystrophy (DMD)
Sites: Shanghai, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.